Literature DB >> 19954280

5T4 as a target for immunotherapy in renal cell carcinoma.

Eyad Elkord, Alaaeldin Shablak, Peter L Stern, Robert E Hawkins.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19954280     DOI： 10.1586/era.09.152

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


× No keyword cloud information.
  3 in total

1.  5T4 oncofetal antigen is expressed in high risk of relapse childhood pre-B acute lymphoblastic leukemia and is associated with a more invasive and chemotactic phenotype.

Authors:  F V Castro; O J McGinn; S Krishnan; G Marinov; J Li; A J Rutkowski; E Elkord; D J Burt; M Holland; R Vaghjiani; A Gallego; V Saha; P L Stern
Journal:  Leukemia       Date:  2012-01-23       Impact factor: 11.528

2.  Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α.

Authors:  Eyad Elkord; Deborah J Burt; Anette Sundstedt; Örjan Nordle; Gunnar Hedlund; Robert E Hawkins
Journal:  Oncotarget       Date:  2015-02-28

Review 3.  Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities.

Authors:  Angela Graves; Hannah Hessamodini; Germaine Wong; Wai H Lim
Journal:  Immunotargets Ther       Date:  2013-07-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.